Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases

Drug Development Research

Volumn 77, Issue 3, 2016, Pages 109-123

  Irwin, Michael H ^a   Moos, Walter H ^b,c   Faller, Douglas V ^d   Steliou, Kosta ^d,e   Pinkert, Carl A ^a,f  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SRI INTERNATIONAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PhenoMatriX Inc   (United States)

^f UNIVERSITY OF ALABAMA   (United States)

Author keywords

Alzheimer; antioxidant; butyrate; carnitine; epigenetic; histone deacetylase; histone deacetylase inhibitors; lipoic acid; mitochondrial dysfunction; neurodegeneration; Parkinson; PMX 500; PMX 550; post traumatic stress disorders; reactive oxygen species

Indexed keywords

CARNITINE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; ANTIOXIDANT; CARNITINE;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; EPIGENETICS; EXECUTIVE FUNCTION; HUMAN; IN VIVO STUDY; LANGUAGE DISABILITY; MEMORY DISORDER; MENTAL CAPACITY; MITOPHAGY; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NEUROPROTECTION; PARKINSON DISEASE; PATHOPHYSIOLOGY; RISK FACTOR; TRAUMATIC BRAIN INJURY; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; MITOCHONDRION; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANTIOXIDANTS; CARNITINE; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MITOCHONDRIA; NEURONAL PLASTICITY; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84958794345     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21294     Document Type: Article

References (283)

1. Adwan L, Zawia NH., 2013. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. Pharmacol Therapeut 139: 41-50.
2. Allen GFG, Toth R, James J, Ganley IG., 2013. Loss of iron triggers PINK1/Parkin-independent mitophagy. EMBO Rep 14: 1127-1135.
3. Ames BN., 2010. Optimal micronutrients delay mitochondrial decay and age-associated diseases. Mech Aging Dev 131: 473-479.
4. Amtul Z., 2016. Why therapies for Alzheimer's disease do not work: do we have consensus over the path to follow? Ageing Res Rev 25: 70-84.
5. Anand R, Gill KD, Mahdi AA., 2014. Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology 76: 27-50.
6. Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, Kügler S, Ikezu T., 2015. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 18: 1584-1593.
7. Ashrafi G, Schwarz TL., 2013. The pathways of mitophagy for quality control and clearance of mitochondria. Nat Cell Death Differ 20: 31-42.
8. Ashrafi G, Schlehe JS, LaVoie MJ, Schwarz TL., 2014. Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. J Cell Biol 206: 655-670.
9. Avila-Muñoz E, Arias C., 2014. When astrocytes become harmful: functional and inflammatory responses that contribute to Alzheimer's disease. Ageing Res Rev 18: 29-40.
10. Aydin B, Hocaoglu N, Gidener S., 2012. Could decitabine treatment impair memory functions in humans? Med Hypothesis 79: 639-641.
11. Barnett R., 2016. Case histories Parkinson's disease. Lancet 387: 217.
12. Bassett SA, Barnett MPG., 2014. The role of dietary histone deacetylases (HDACs) inhibitors in health and disease. Nutrients 6: 4273-4301.
13. Bieber LL., 1988. Carnitine. Ann Rev Biochem 57: 261-283.
14. Bieber LL, Emaus R, Valkner K, Farrell S., 1982. Possible functions of short-chain and medium-chain carnitine acyltransferases. Fed Proc 41: 2858-2862.
15. Billhardt U-M, Stein P, Whitesides GM., 1989. Enzymatic methods for the preparation of acetyl-CoA and analogs. Bioorg Chem 17: 1-12.
16. Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q, Foreman O, Kirkpatrick DS, Sheng M., 2014. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 510: 370-375.
17. Boison D, Aronica E., 2015. Comorbidities in neurology: is adenosine the common link? Neuropharmacology 97: 18-34.
18. Bolaños JP, Moro MA, Lizasoain I, Almeida A., 2009. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: therapeutic implications. Adv Drug Deliv Rev 61: 1299-1315.
19. Breuer ME, Willems PHGM, Russel FGM, Koopman WJH, Smeitink JAM., 2012. Modeling mitochondrial dysfunctions in the brain: from mice to men. J Inherit Metab Dis 35: 193-210.
20. Breuer ME, Koopman WJ, Koene S, Nooteboom M, Rodenburg RJ, Willems PH, Smeitink JAM., 2013. The role of mitochondrial OXPHOS dysfunction in the development of neurologic diseases. Neurobiol Dis 51: 27-34.
21. Brown SE, Ross MF, Sanjuan-Pla A, Manas A-RB, Smith RAJ, Murphy MP., 2007. Targeting lipoic acid to mitochondria: synthesis and characterization of a triphenylphosphonium-conjugated α-lipoyl derivative. Free Radic Bio Med 42: 1766-1780.
22. Brück D, Wenning GK, Stefanova N, Fellner L., 2016. Glia and alpha-synuclein in neurodegeneration: a complex interaction. Neurobiol Dis 85: 262-274.
23. Buccafusco JJ., 2009. Emerging cognitive enhancing drugs. Expert Opin Emerging Drugs 14: 577-589.
24. Burns A, Byrne EJ, Maurer K., 2002. Alzheimer's disease. Lancet 360: 163-165.
25. Busche MA, Grienberger C, Keskin AD, Song B, Neumann U, Staufenbiel M, Förstl H, Konnerth A., 2015. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models. Nat Neurosci 18: 1725-1727.
26. Byun H-M., Baccarelli AA., 2014. Environmental exposure and mitochondrial epigenetics: study design and analytical challenges. Hum Genet 133: 247-257.
27. Calvo AC, Manzano R, Mendonça DMF, Muñoz MJ, Zaragoza P, Osta R., 2014. Amyotrophic lateral sclerosis: a focus on disease progression. Biomed Res Int 2014: ID 925101.
28. Canani RB, Di Costanzo M, Leone L., 2012. The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. Clin Epigenet 4: 4.
29. Carlson DA, Smith AR, Fischer SJ, Young KL, Packer L., 2007. The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects. Altern Med Rev 12: 343-351.
30. Carrasco-Pozo C, Tan KN, Borges K., 2015. Sulforaphane is anticonvulsant and improves mitochondrial function. J Neurochem 135: 932-942.
31. Carvalho C, Cardoso S, Correia SC, Santos RX, Santos MS, Baldeiras I, Oliveira CR, Moreira PI., 2012. Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Diabetes 61: 1234-1242.
32. Chan V, Thurairajah P, Colantonio A., 2015. Defining pediatric traumatic brain injury using International Classification of Diseases Version 10 Codes: a systematic review. BMC Neurology 15: 7.
33. Chaturvedi RK, Beal MF., 2013. Mitochondrial diseases of the brain. Free Radic Bio Med 63: 1-29.
34. Chen C, Li X-H, Zhang S, Tu Y, Wang Y-M, Sun H-T., 2014. 7,8-Dihydroxyflavone ameliorates scopolamine-induced Alzheimer-like pathologic dysfunction. Rejuv Res 17: 249-254.
35. Chenault HK, Simon ES, Whitesides GM., 1988. Cofactor regeneration for enzyme-catalysed synthesis. Biotechnol Genet Eng Rev 6: 221-270.
36. Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A, Martins RN, Rowe CC, Macaulay SL, Masters CL, Hill AF., 2015. Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. Nat Mol Psychiatry 20: 1188-1196.
37. Choi AMK, Ryter SW, Levine B., 2013. Autophagy in human health and disease. N Engl J Med 368: 651-662.
38. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, et al., 2014. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 514: 274-278.
39. Choong C-J, Sasaki T, Hayakawa H, Yasuda T, Baba K, Hirata Y, Uesato S, Mochizuki H., 2016. A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson's disease. Neurobiol Aging 37: 103-116.
40. Chuang D-M, Leng Y, Marinova Z, Kim H-J, Chiu C-T., 2009. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32: 591-601.
41. Chung H, Dai T, Sharma SK, Huang Y-Y, Carroll JD, Hamblin MR., 2012. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng 40: 516-533.
42. Chung W-S, Welsh CA, Barres BA, Stevens B., 2015. Do glia drive synaptic and cognitive impairment in disease? Nat Neurosci 18: 1539-1545.
43. Coppedè F., 2014. The potential of epigenetic therapies in neurodegenerative diseases. Front Genet 5: ID 220.
44. Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, et al., 2012. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335: 1503-1506.
45. Currais A., 2015. Ageing and inflammation-a central role for mitochondria in brain health and disease. Ageing Res Rev 21: 30-42.
46. Danta CC, Piplani P., 2014. The discovery and development of new potential antioxidant agents for the treatment of neurodegenerative diseases. Expert Opin Drug Discov 9: 1205-1222.
47. Dashwood RH, Ho E., 2007. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 17: 363-369.
48. Daulatzai MA., 2015. Evidence of neurodegeneration in obstructive sleep apnea: relationship between obstructive sleep apnea and cognitive dysfunction in the elderly. J Neurosci Res 93: 1778-1794
49. de Boer VCJ, Houten SM., 2014. A mitochondrial expatriate: nuclear pyruvate dehydrogenase. Cell 158: 9-10.
50. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, Eaton ML, Keenan BT, Ernst J, McCabe C, et al., 2014. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci 17: 1156-1163.
51. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, Bäckhed F, Mithieux G., 2014. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156: 84-96.
52. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, et al., 2012. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122: 1377-1392.
53. Denzer I, Münch G, Friedland K., 2016. Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds. Pharmacol Res 103: 80-94.
54. Dhanak D., 2012. Cracking the code: the promise of epigenetics. ACS Med Chem Lett 3: 521-523.
55. Dinkova-Kostova AT, Abramov AY., 2015. The emerging role of Nrf2 in mitochondrial function. Free Radic Bio Med 88: 179-188.
56. 2). Toxicol Rep 2: 78-87.
57. Dmitriev RI, Papkovsky DB., 2015. In vitro ischemia decreases histone H4K16 acetylation in neural cells. FEBS Lett 589: 138-144.
58. Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ., 2012. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell 48: 612-626.
59. Dörsam B, Göder A, Seiwert N, Kaina B, Fahrer J., 2015. Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil. Arch Toxicol 89: 1829-1846.
60. Dörsam B, Fahrer J., 2016. The disulfide compound α-lipoic acid and its derivatives: a novel class of anticancer agents targeting mitochondria. Cancer Lett 371: 12-19.
61. Doshi-Velez F, Ge Y, Kohane I., 2014. Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis. Pediatrics 133: e54-e63.
62. El-Hattab AW, Scaglia F., 2015. Disorders of carnitine biosynthesis and transport. Mol Genet Metabol 116: 107-112.
63. Endo H, Niioka M, Kobayashi N, Tanaka M, Watanabe T., 2013. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLoS One 8: e63388.
64. Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H, Mahlakoiv T, Jakobshagen K, Buch T, et al., 2015. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18: 965-977.
65. Estes ML, McAllister AK., 2015. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat Rev Neurosci 16: 469-486.
66. Fahn S., 2015. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 30: 4-18.
67. Falkenberg KJ, Johnstone RW., 2014. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13: 673-691.
68. Faul M, Xu L, Wald MM, Coronado VG., 2010. Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths 2002-2006. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. http://www.cdc.gov/TraumaticBrainInjury/severe.html, accessed February 15, 2016.
69. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E., 2012. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 322: 254-262.
70. Feil SC, Holien JK, Morton CJ, Hancock NC, Thompson PE, Parker MW., 2014. Discovery of phosphodiesterase-4 inhibitors: serendipity and rational drug design. Aust J Chem 67: 1780-1785.
71. Fernández-Galilea M, Pérez-Matute P, Prieto-Hontoria PL, Houssier M, Burrell MA, Langin D, Martínez JA, Moreno-Aliaga MJ., 2015. α-Lipoic acid treatment increases mitochondrial biogenesis and promotes beige adipose features in subcutaneous adipocytes from overweight/obese subjects. BBA-Mol Cell Biol Lipid 1851: 273-281.
72. Fernández-Moriano C, González-Burgos E, Gómez-Serranillos MP., 2015. Mitochondria-targeted protective compounds in Parkinson's and Alzheimer's diseases. Oxid Med Cell Longev 2015:ID 408927 (http://dx.doi.org/10.1155/2015/408927).
73. Fidan E, Lewis J, Kline AE, Garman RH, Alexander H, Cheng JP, Bondi CO, Clark R, Dezfulian C, Kochanek PM, et al., 2015. Repetitive mild traumatic brain injury in the developing brain: effects on long-term functional outcome and neuropathology. J Neurotrauma (December 1, doi: 10.1089/neu.2015.3958).
74. Fonseca MI, Ager RR, Chu S-H, Yazan O, Sanderson SD, LaFerla FM, Taylor SM, Woodruff TM, Tenner AJ., 2009. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol 183: 1375-1383.
75. Forbes-Hernández TY, Giampieri F, Gasparrini M, Mazzoni L, Quiles JL, Alvarez-Suarez JM, Battino M., 2014. The effects of bioactive compounds from plant foods on mitochondrial function: a focus on apoptotic mechanisms. Food Chem Toxicol 68: 154-182.
76. Forsyth JK, Bachman P, Mathalon DH, Roach BJ, Asarnow RF., 2015. Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain. Proc Natl Acad Sci USA 11: 15331-15336.
77. Frake RA, Ricketts T, Menzies FM, Rubinsztein DC., 2015. Autophagy and neurodegeneration. J Clin Invest 125: 65-74.
78. Friedman JR, Nunnari J., 2014. Mitochondrial form and function. Nature 505: 335-343.
79. Fukasawa H, Nakagomi M, Yamagata N, Katsuki H, Kawahara K, Kitaoka K, Miki T, Shudo K., 2012. Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull 35: 1206-1212.
80. Gajavelli S, Sinha VK, Mazzeo AT, Spurlock MS, Lee SW, Ahmed AI, Yokobori S, Bullock RM., 2015. Evidence to support mitochondrial neuroprotection, in severe traumatic brain injury. J Bioenerg Biomembr 47: 133-148.
81. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, et al., 2012. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69: 836-841.
82. Gerald Z, Ockert W., 2013. Alzheimer's disease market: hope deferred. Nat Rev Drug Discov 12: 19-20.
83. Ghezzi L, Scarpini E, Galimberti D., 2013. Disease-modifying drugs in Alzheimer's disease. Drug Design Ther 7: 1471-1479.
84. Gibson CJ, Davids MS., 2015. BCL-2 Antagonism to target the intrinsic mitochondrial pathway of apoptosis. Clin Cancer Res 21: 5021-5029.
85. Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai L-H, Kellis M., 2015. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature 518: 365-369.
86. Godyń J, Jończyk J, Panek D, Malawska B., 2016. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol Rep 68: 127-138.
87. Gomes LC, Scorrano L., 2013. Mitochondrial morphology in mitophagy and macroautophagy. BBA-Mol Cell Res 1833: 205-212.
88. Gomes MB, Negrato CA., 2014. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr 6: 80.
89. Gong X-W, Li J-P, Wu J-F, Li X, Zhai H-M, Feng B, Wen-Fang Xu W-F, 2008. Synthesis of carnitine benzyl esters as prodrugs. J Chem Res 2008: 327-330.
90. G orąca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, Skibska B., 2011. Lipoic acid-biological activity and therapeutic potential. Pharmacol Rep 63: 849-858.
91. Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A., 2012. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis 26: 187-197.
92. Gräff J, Rei D, Guan J-S, Wang W-Y, Seo J, Hennig KM, Nieland TJF, Fass DM, Kao PF, Kahn M, et al., 2012. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483: 222-226.
93. Grayson DR, Kundakovic M, Sharma RP., 2010. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 77: 126-135.
94. Gurney ME, D'Amato EC, Burgin AB., 2015. Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease. Neurotherapeutics 12: 49-56.
95. Harrison IF, Dexter DT., 2013. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Pharmacol Therapeut 140: 34-52.
96. Hattori N., 2016. Movement disorders: advances in 2015. Lancet Neurol 15: 8-9.
97. Hattori N, Saiki S, Imai Y., 2014. Regulation by mitophagy. Int J Biochem Cell Biol 53: 147-150.
98. Hnia K, Hugon G, Rivier F, Masmoudi A, Mercier J, Mornet D., 2007. Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient mdx mice. Am J Pathol 170: 633-643.
99. Houten SM, Wanders RJA., 2010. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis 33: 469-477.
100. Husain M, Mehta MA., 2011. Cognitive enhancement by drugs in health and disease. Trends Cogn Sci 15: 28-36.
101. Irwin MH, Parameshwaran K, Pinkert CA., 2013. Mouse models of mitochondrial complex I dysfunction. Int J Biochem Cell Biol 45: 34-40.
102. Jack CR Jr, Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Mielke MM, Vemuri P, Roberts RO, Machulda MM, et al., 2016. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol 15: 56-64.
103. Jakovcevski M, Akbarian S., 2012. Epigenetic mechanisms in neurological disease. Nat Med 18: 1194-1204.
104. Jin SM, Youle RJ., 2012. PINK1 and Parkin mediated mitophagy at a glance. J Cell Sci 125: 795-799.
105. Johnson CA, Johnson JA., 2015. Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Bio Med 88: 253-267.
106. Jones LL, McDonald DA, Borum PR., 2010. Acylcarnitines: role in brain. Prog Lipid Res 49: 61-75.
107. Joshi G, Gan KA, Johnson DA, Johnson JA., 2015. Increased Alzheimer's disease-like pathology in the APP/PS1DE9 mouse model lacking Nrf2 through modulation of autophagy. Neurobiol Aging 36: 664-679.
108. Jyothi HJ, Vidyadhara DJ, Mahadevan A, Philip M, Parmar SK, Manohari SG, Shankar SK, Raju TR, Alladi PA., 2015. Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta. Neurobiol Aging 36: 3321-3333.
109. Kalia LV, Kalia SK, Lang AE., 2015. Disease-modifying strategies for Parkinson's Disease. Mov Disord 30: 1442-1450.
110. Kane LA, Youle RJ., 2012. PINK1 and Parkin flag Miro to direct mitochondrial traffic. Cell 147: 721-723.
111. Karagiannis TC, Maulik N., 2012. Factors influencing epigenetic mechanisms and related diseases. Antioxid Redox Sign 17: 192-194.
112. Karagiannis TC, Ververis K., 2012. Potential of chromatin modifying compounds for the treatment of Alzheimer's disease. Pathobiol Aging Age-related Dis 2: 14980.
113. Karran E, Hardy J., 2014. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Annal Neurol 76. 185-205.
114. Kazlauskaite A, Muqit MMK., 2015. PINK1 and Parkin-mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease. FEBS J 282: 215-223.
115. Keith DJ, Butler JA, Bemer B, Dixon B, Johnson S, Garrard M, Sudakin DL, Christensen JM, Pereira C, Hagen TM., 2012. Age and gender dependent bioavailability of R- and R,S- α-lipoic acid: a pilot study. Pharmacol Res 66: 199-206.
116. Klinedinst NJ, Regenold WT., 2015. A mitochondrial bioenergetic basis of depression. J Bioenerg Biomembr 47: 155-171.
117. Knoop F., 1904. Der abbau aromatischer fettsäuren im tierkörper (The degradation of aromatic fatty acids in the animal body). Beitr Chem Physiol Pathol 6: 150-162.
118. Kochanek PM, Clark RSB., 2016. Traumatic brain injury research highlights in 2015. Lancet Neurol 15: 13-15.
119. Kratsman N, Getselter D, Evan Elliott E., 2016. Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model. Neuropharmacology 102: 136-145.
120. Krishna S, Brown N, Faller DV, Spanjaard RA., 2002. Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells. Laryngoscope 112: 645-650.
121. Kroemer G., 2015. Autophagy: a druggable process that is deregulated in aging and human disease. J Clin Invest 125: 1-4.
122. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, Ziller MJ, et al., 2015. Integrative analysis of 111 reference human epigenomes. Nature 518: 317-330.
123. LaFerla FM., 2012. Preclinical success against Alzheimer's disease with an old drug. N Engl J Med 367: 570-572.
124. Laforge M, Rodrigues V, Silvestre R, Gautier C, Weil R, Corti O, Estaquier J., 2016. NF-κB pathway controls mitochondrial dynamics. Nat Cell Death Differ 23: 89-98.
125. Lane RK, Hilsabeck T, Rea SL., 2015. The role of mitochondrial dysfunction in age-related diseases. BBA-Bioenergetics 1847: 1387-1400.
126. Laurijssens B, Aujard F, Rahman A., 2013. Animal models of Alzheimer's disease and drug development. Drug Discov Today Technol 10: e319-e327.
127. Lazarou M, Jin SM, Kane LA, Youle RJ., 2012. Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin. Dev Cell 22: 230-233.
128. Lee J-H, Yao Y, Mahendran A, Ngo L, Venta-Perez G, Choy ML, Breslow R, Marks PA., 2015. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc Natl Acad Sci USA 112: 12005-12010.
129. th Birthday. Mov Disord 22: S327-S334.
130. Lewczuk P, Mroczko B, Fagan A, Kornhuber J., 2015. Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective. Adv Med Sci 60: 76-82.
131. Li S., 2015. Synthetic bioactive substances, In: PCK, Mehta BM, editors. Handbook of food chemistry, Berlin, Springer-Verlag. p 1-20.
132. Li Y-H, He Q, Yu J-z, Liu C-y, Feng L, Chai Z, Wang Q, Zhang H-z, Zhang G-X, Xiao B-g, et al., 2015. Lipoic acid protects dopaminergic neurons in LPS-induced Parkinson's disease model. Metab Brain Dis 30: 1217-1226.
133. Lin M, Beal MF., 2006. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795.
134. Lionaki E, Markaki M, Palikaras K, Tavernarakis N., 2015. Mitochondria, autophagy and age-associated neurodegenerative diseases: new insights into a complex interplay. BBA-Bioenergetics 1847: 1412-1423.
135. Liu J, Killilea DW, Ames BN., 2002a. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and or R-α-lipoic acid. Proc Natl Acad Sci USA 99: 1876-1881.
136. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames BN., 2002b. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-α-lipoic acid. Proc Natl Acad Sci USA 99: 2356-2361.
137. Lunnon K, Mill J., 2013. Epigenetic studies in Alzheimer's Disease: current findings, caveats, and considerations for future studies. Am J Med Genet Part B 162B: 789-799.
138. Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, Münch G., 2008. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv Drug Deliver Rev 60: 1463-1470.
139. Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M, Chen G., 2012. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci 13: 293-307.
140. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, et al., 2014. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20: 415-418.
141. Maqbool M, Mobashir M, Hoda N., 2016. Pivotal role of glycogen synthase kinase-3: a therapeutic target for Alzheimer's disease. Eur J Med Chem 107: 63-81.
142. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J., 2011. Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging 32: 1161-1180.
143. Matic I, Strobbe D, Frison M, Campanella M., 2015. Controlled and impaired mitochondrial quality in neurons: molecular physiology and prospective pharmacology. Pharmacol Res 99: 410-424.
144. Matt SM, Johnson RW., 2016. Neuro-immune dysfunction during brain aging: new insights in microglial cell regulation. Curr Opin Pharmacol 26: 96-101.
145. Mayr JA, Feichtinger RG, Tort F, Wolfgang Sperl W., 2014. Lipoic acid biosynthesis defects. J Inherit Metab Dis 37: 553-563.
146. McLelland G-L, Soubannier V, Chen CX, McBride HM, Fon EA., 2014. Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. EMBO J 33: 282-295.
147. Mecocci P, Polidori MC., 2012. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. BBA-Mol Basis Dis 1822: 631-638.
148. Melser S, Lavie J, Bénard G., 2015. Mitochondrial degradation and energy metabolism. BBA-Mol Cell Res 1853: 2812-2821.
149. Mhatre SD, Tsai CA, Rubin AJ, James ML, Andreasson KI., 2015. Microglial malfunction: the third rail in the development of Alzheimer's disease. Trends Neurosci 38: 621-636.
150. Millan MJ., 2013. An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. Neuropharmacology 68: 2-82.
151. Miller G., 2010. The puzzling rise and fall of a dark-horse Alzheimer's drug. Science 327: 1309.
152. Milone M., 2012. Mitochondria, diabetes, and Alzheimer's disease. Diabetes 61: 991-992.
153. Mishra P, Chan DC., 2014. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Bio 15: 634-646.
154. Monaghan RM, Whitmarsh AJ., 2015. Mitochondrial proteins moonlighting in the nucleus. Trends Biochem Sci 40: 728-735.
155. Moore SF, Barker RA., 2014. Predictors of Parkinson's disease dementia: towards targeted therapies for a heterogeneous disease. Parkinsonism Relat Disord 20S1: S104-S107.
156. Moos WH, Maneta E, Pinkert CA, Irwin MH, Hoffman ME, Faller DV, Steliou K., 2016. Epigenetic treatment of neuropsychiatric disorders: Autism and Schizophrenia. Drug Dev Res, in press.
157. Moreira PI, Zhu X, Wang X, Lee H-g, Nunomura A, Petersen RB, Perry G, Smith MA., 2010. Mitochondria: a therapeutic target in neurodegeneration. BBA-Mol Basis Dis 1802: 212-220.
158. Morris JK, Honea RA, Vidoni ED, Swerdlow RH, Burns JM., 2014. Is Alzheimer's disease a systemic disease? BBA-Mol Basis Dis 1842: 1340-1349.
159. Moschetti K, Cummings PL, Sorvillo F, Kuo T., 2012. Burden of Alzheimer's disease-related mortality in the United States, 1999-2008. J Am Geriatr Soc 60: 1509-1514.
160. Mullane K, Williams M., 2013. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 85: 289-305.
161. Nałezcz KA, Miecz D, Berezowski V, Cecchelli R., 2004. Carnitine: transport and physiological functions in the brain. Mol Aspects Med 25: 551-567.
162. Narayan PJ, Lill C, Faull R, Curtis MA, Dragunow M., 2015. Increased acetyl and total histone levels in post-mortem Alzheimer's disease brain. Neurobiol Dis 74: 281-294.
163. Narendra DP, Youle RJ., 2011. Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid Redox Signal 14: 1929-1938.
164. Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, Battaglia G, Mathé AA, Pittaluga A, Lionetto L, et al., 2013. L-Acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA 110: 4804-4809.
165. Natarajan N, Pluznick JL., 2014. From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Am J Physiol Cell Physiol 307: C979-C985.
166. Nebbioso A, Carafa V, Benedetti R, Lucia Altucci L., 2012. Trials with 'epigenetic' drugs: an update. Mol Oncol 6: 657-682.
167. Neltner JH, Abner EL, Jicha GA, Schmitt FA, Patel E, Poon LW, Marla G, Green RC, Davey A, Johnson MA, et al., 2016. Brain pathologies in extreme old age. Neurobiol Aging 37: 1-11.
168. Nicolson GL, Settineri R, Ellithorpe RR., 2014. Neurodegenerative and fatiguing illnesses, infections and mitochondrial dysfunction: use of natural supplements to improve mitochondrial function. Funct Food Health Dis 4: 23-65.
169. Nikoletopoulou V, Papandreou M-E, Tavernarakis N., 2015. Autophagy in the physiology and pathology of the central nervous system. Nat Cell Death Differ 22: 398-407.
170. Novak I., 2012. Mitophagy: a complex mechanism of mitochondrial removal. Antioxid Redox Sign 17: 794-802.
171. Oettinghaus B, Schulz JM, Restelli LM, Licci M, Savoia C, Schmidt A, Schmitt K, Grimm A, Morè L, Hench J, et al., 2016. Synaptic dysfunction, memory deficits and hippocampal atrophy due to ablation of mitochondrial fission in adult forebrain neurons. Nat Cell Differ 23: 18-28.
172. Oliveras-Salvá M, Macchi F, Coessens V, Deleersnijder A, Gérard M, Van der Perren A, Van den Haute C, Baekelandt V., 2014. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice. Neurobiol Aging 35: 2625-2636.
173. Olson KE, Gendelman HE., 2016. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Curr Opin Pharmacol 26: 87-95.
174. Osborne NN, Álvarez CN, del Olmo Aguado S., 2014. Targeting mitochondrial dysfunction as in aging and glaucoma. Drug Discov Today 19: 1613-1622.
175. Pagano G, Talamanca AA, Castello G, Cordero MD, d'Ischia M, Gadaleta MN, Pallardó FV, Petrovic S, Tiano L, Zatterale A., 2014. Oxidative stress and mitochondrial dysfunction across broad-ranging pathologies: toward mitochondria-targeted clinical strategies. Oxid Med Cell Longev 2014: 1.
176. Palikaras K, Tavernarakis N., 2014. Mitochondrial homeostasis: the interplay between mitophagy and mitochondrial biogenesis. Exp Gerontol 56: 182-188.
177. Papanas N, Ziegler D., 2015. Efficacy of α-lipoic acid in diabetic retinopathy. Expert Opin Pharmacother 15: 2721-2731.
178. Parameshwaran K, Irwin MH, Steliou K, Pinkert CA., 2010. D-Galactose effectiveness in modeling aging and therapeutic antioxidant treatment in mice. Rejuv Res 13: 729-735.
179. Parameshwaran K, Irwin MH, Steliou K, Pinkert CA., 2012. Protection by an antioxidant of rotenone-induced neuromotor decline, reactive oxygen species generation and cellular stress in mouse brain. Pharmacol Biochem Behav 101: 487-492.
180. Parameshwaran K, Irwin MH, Steliou K, Suppiramaniam V, Pinkert CA., 2015. Antioxidant-mediated reversal of oxidative damage in mouse modeling of complex I inhibition. Drug Dev Res 76: 72-81.
181. Pashaj A, Xia M, Moreau R., 2015. α-Lipoic acid as a triglyceride-lowering nutraceutical. Can J Physiol Pharmacol 93: 1.
182. Payne BAI, Chinnery PF., 2015. Mitochondrial dysfunction in aging: much progress but many unresolved questions. BBA-Bioenergetics 1847: 1347-1353.
183. Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, Agis-Balboa RC, Wittnam JL, Gogol-Doering A, Opitz L, et al., 2010. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328: 753-756.
184. Pellegrino MW, Haynes CM., 2015. Mitophagy and the mitochondrial unfolded protein response in neurodegeneration and bacterial infection. BMC Biology 13: 22.
185. Piaceri I, Rinnoci V, Bagnoli S, Failli Y, Sorbi S., 2012. Mitochondria and Alzheimer's disease. J Neurol Sci 322: 31-34.
186. Pickrell AM, Youle RJ., 2015. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 85: 257-273.
187. Piermatti O, Fringuelli F, Pochini L, Indiveri C, Palmerini CA., 2008. Synthesis and characterization of carnitine nitro-derivatives. Bioorg Med Chem 16: 1444-1451.
188. Pinho CM, Teixeira PF, Glaser E., 2014. Mitochondrial import and degradation of amyloid-β peptide. BBA-Bioenergetics 1837: 1069-1174.
189. Pinto M, Moraes CT., 2014. Mitochondrial genome changes and neurodegenerative diseases. BBA-Mol Basis Dis 1842: 1198-1207.
190. Plesnila N., 2016. The immune system in traumatic brain injury. Curr Opin Pharmacol 26: 110-117.
191. Prasad KN., 2015. Simultaneous activation of Nrf2 and elevation of antioxidant chemicals in management of post-traumatic stress disorders and traumatic brain injury. Balkan Military Med Rev 18: 116-127.
192. Qian XX, Hamad B, Dias-Lalcaca G., 2015. The Alzheimer disease market. Nat Rev Drug Discov 14: 675-676.
193. Qureshi IA, Mehler MF., 2014. Epigenetic mechanisms underlying the pathogenesis of neurogenetic diseases. Neurotherapeutics 11: 708-720.
194. Rai PK, Russell OM, Lightowlers RN, Turnbull DM., 2015. Potential compounds for the treatment of mitochondrial disease. Br Med Bull 116: 5-18.
195. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Moreno-Sánchez R., 2010. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 31: 29-59.
196. Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, Shirendeb UP, Calkins MJ, Reddy AP, Mao P, et al., 2012. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. BBA-Mol Basis Dis 1822: 639-649.
197. Redmann M, Dodson M, Boyer-Guittaut M, Darley-Usmar V, Zhang J., 2014. Mitophagy mechanisms and role in human diseases. Int J Biochem Cell Biol 53: 127-133.
198. Ribas GS, Vargas CR, Wajner M., 2014. L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Gene 533: 469-476.
199. Ricobaraza A, Cuadrado-Tejedor M, Marco S, Pérez-Otanõ I, García-Osta A., 2012. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 22: 1040-1050.
200. Riera CE, Dillin A., 2016. Can aging be 'drugged'? Nat Med 21: 1400-1405.
201. Ripcke J, Zarse K, Ristow M, Birringer M., 2009. Small-molecule targeting of the mitochondrial compartment with an endogenously cleaved reversible tag. ChemBioChem 10: 1698-1696.
202. Rochette L, Ghibu S, Richard C, Zeller M, Cottin Y, Vergely C., 2013. Direct and indirect antioxidant properties of alpha-lipoic acid and therapeutic potential. Mol Nutr Food Res 57: 114-125.
203. Rochette L, Ghibu S, Muresan A, Vergely C., 2015. Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol 93: 1.
204. Roos-Araujo D, Stuart S, Lea RA, Haupt LM, Griffiths LR., 2014. Epigenetics and migraine; complex mitochondrial interactions contributing to disease susceptibility. Gene 533: 1-7.
205. Rosca MG, Lemieux H, Hoppel CL,. 2009. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? Adv Drug Deliv Rev 61: 1332-1342.
206. Rosenstock TR., 2013. Lysine (K)-deacetylase inhibitors: the real next step to neuropsychiatric and neurodegenerative disorders? Cell Biol 2: a8.
207. Rosini M, Simoni E, Bartolini M, Tarozzi A, Matera R, Milelli A, Hrelia P, Andrisano V, Bolognesi ML, Melchiorre C., 2011. Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. Eur J Med Chem 46: 5435-5442.
208. Rosow K, Holzapfel A, Karlawish JH, Baumgart M, Baind LJ, Khachaturian AS., 2011. Countrywide strategic plans on Alzheimer's disease: developing the framework for the international battle against Alzheimer's disease. Alzheimer's Dement 7: 615-621.
209. Rubiano AM, Carney N, Chesnut R, Puyana JC., 2015. Global neurotrauma research challenges and opportunities. Nature 527: S193-S197.
210. Ryan NS, Rossor MN, Fox NC., 2015. Alzheimer's disease in the 100 years since Alzheimer's death. Brain 138: 3816-3821.
211. Salama AF, Ibrahim W, Tousson E, Sakr S, Masoud A, Akela MA, Abd El-Rahman MA., 2015. Epigenetic study of Parkinson's disease in experimental animal model. Int J Clin Exp Neurol 3: 11-20.
212. Salminen A, Kauppinen A, Hiltunen M, Kaarnirant K., 2014. Krebs cycle intermediates regulate DNA and histone methylation: epigenetic impact on the aging process. Ageing Res Rev 15: 45-65.
213. Sarosiek KA, Chonghaile TN, Letai A., 2013. Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol 23: 612-619.
214. Savonenko AV, Melnikova T, Hiatt A, Li T, Worley PF, Troncoso JC, Wong PC, Price DL., 2012. Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Nat Neuropsychopharmacol 37: 261-277.
215. Schapira AHV., 2012. Mitochondrial diseases. Lancet 379: 1825-1834.
216. Schneider JL, Cuervo AM., 2014. Autophagy and human disease: emerging themes. Curr Opin Genet Dev 26: 16-23.
217. Selfridge JE, Lezi E, Lu J, Swerdlow RH., 2013. Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. Neurobiol Dis 51: 3-12.
218. Selkoe DJ., 2012. Preventing Alzheimer's disease. Science 337: 1488-1491.
219. Sezgin Z, Dincer Y., 2014. Alzheimer's disease and epigenetic diet. Neurochem Int 78: 105-116.
220. Shearer KD, Stoney PN, Morgan PJ, McCaffery PJ., 2012. A vitamin for the brain. Trends Neurosci 35: 733-741.
221. Shenk JC, Liu J, Fischbach K, Xu K, Puchowicz M, Obrenovich ME, Gasimov E, Alvarez LM, Ames BN, LaManna JC, et al., 2009. The effect of acetyl-L-carnitine and R-α-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J Neurol Sci 283: 199-206.
222. Sheridan C., 2015. Pivotal trials for β-secretase inhibitors in Alzheimer's. Nat Biotechnol 33: 115-116.
223. Singh S, Mishra A, Shukla S., 2015. ALCAR exerts neuroprotective and pro-neurogenic effects by inhibition of glial activation and oxidative stress via activation of the Wnt/β-catenin signaling in Parkinsonian rats. Mol Neurobiol (July 30, doi: 10.1007/s12035-015-9361-5).
224. Smith R, Mill J., 2011. Epigenetics and chronic diseases: an overview. In: Roach HI, Bronner F, Oreffo ROC, editors. Epigenetic aspects of chronic diseases. London: Springer-Verlag.
225. Sodhi N, Jaggi AS, Singh N., 2014. Animal models of dementia and cognitive dysfunction. Life Sci 109: 73-86.
226. Sorci G, Riuzzi F, Giambanco I, Donato R., 2013. RAGE in tissue homeostasis, repair and regeneration. BBA-Mol Cell Res 1833: 101-109.
227. Sozio P, Cerasa LS, Laserra S, Cacciatore I, Cornacchia C, Di Filippo ES, Fulle S, Fontana A, Di Crescenzo A, Grilli M, et al., 2013. Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease. Eur J Pharm Sci 49: 187-198.
228. Spalding MD, Sean T, Prigge ST., 2010. Lipoic acid metabolism in microbial pathogens. Microbiol Mol Biol Rev 74: 200-228.
229. 0,+. Am J Physiol Gastrointest Liver Physiol 293: G1046-G1053.
230. Stacpoole PW., 2012. The pyruvate dehydrogenase complex as a therapeutic target for age-related diseases. Aging Cell 11: 371-377.
231. Steer EK, Dail MK, Chu CT., 2015. Beyond mitophagy: cytosolic PINK1 as a messenger of mitochondrial health. Antioxid Redox Signal 22: 1047-1059.
232. Steliou K, Perrine SP, Faller DV., 2009. Lactic acid in cancer and mitochondrial disease. Drug Dev Res 70: 499-511.
233. Steliou K, Boosalis MS, Perrine SP, Sangerman J, Faller DV., 2012. Butyrate histone deacetylase inhibitors. BioResearch Open Access. 1: 192-198.
234. Steliou K, Faller DV, Pinkert CA, Irwin MH, Moos WH., 2015. Bioprotective Carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury. Drug Dev Res 76: 167-175.
235. Strappazzon F, Nazio F, Corrado M, Cianfanelli V, Romagnoli A, Fimia GM, Campello S, Nardacci R, Piacentini M, Campanella M, et al., 2015. AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1. Nat Cell Death Differ 22: 419-432.
236. Strittmatter WJ., 2012. Old drug, new hope for Alzheimer's disease. Science 335: 1447-1448.
237. Su B, Wang X, Bonda D, Perry G, Smith M, Zhu X., 2010. Abnormal mitochondrial dynamics-A novel therapeutic target for Alzheimer's disease? Mol Neurobiol 41: 87-96.
238. Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu R-M, Hagen TM., 2004. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA 101: 3381-3386.
239. Suliman HB, Piantadosi CA., 2016. Mitochondrial quality control as a therapeutic target. Pharmacol Rev 68: 20-48.
240. Sun N, Yun J, Liu J, Malide D, Liu C, Rovira II, Holmström KM, Fergusson MM, Yoo YH, Combs CA, et al., 2015. Measuring in vivo mitophagy. Mol Cell 60: 685-696.
241. Sung YM, Lee T, Yoon H, DiBattista AM, Song JM, Sohn Y, Moffat EI, Turner RS, Jung M, Kim J, et al., 2013. Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp Neurol 239: 192-201.
242. Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A, Hashimoto K, Zhang N, Flaim E, Michelakis ED., 2014. A nuclear pyruvate dehydrogenase complex is important for the generation of Acetyl-CoA and histone acetylation. Cell 158: 84-97.
243. Sweatt JD., 2013. The emerging field of neuroepigenetics. Neuron 80: 624-632.
244. Swerdlow RH., 2012. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid Redox Sign 16: 1434-1455.
245. Swerdlow RH, Burns JM, Khan SM., 2014. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. BBA-Mol Basis Dis 1842: 1219-1231.
246. Szyf M., 2015. Prospects for the development of epigenetic drugs for CNS conditions. Nat Rev Drug Discov 14: 461-474.
247. Tauskela JS., 2007. Drug evaluation: MitoQ-a mitochondria-targeted antioxidant. IDrugs 10: 399-412.
248. Tayeb HO, Yang HD, Price BH, Tarazi FI., 2012. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Therapeut 134: 8-25.
249. Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, Hayes JD., 2015. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Bio Med 88: 108-146.
250. Tejada-Vera B., 2013. Mortality from Alzheimer's disease in the United States: data for 2000 and 2010. NCHS Data Brief No. 116, March 2013.
251. Thomas EA., 2009. Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Mol Neurobiol 40: 33-45.
252. Tillement L, Lecanu L, Papadopoulos V., 2011. Alzheimer's disease: effects of β-amyloid on mitochondria. Mitochondrion 11: 13-21.
253. Trempe J-F, Sauvé V, Grenier K, Seirafi M, Tang MY, Ménade M, Al-Abdul-Wahid S, Krett J, Wong K, Kozlov G, et al., 2013. Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science 340: 1451-1455.
254. Tripathy D, Chakraborty J, Mohanakumar KP., 2015. Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease. Free Radic Res 49: 1129-1139.
255. Tufi R, Gandhi S, de Castro IP, Lehmann S, Angelova PR, Dinsdale D, Deas E, Plun-Favreau H, Nicotera P, Abramov AY, et al., 2014. Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. Nat Cell Biol 16: 157-166.
256. Ullah F, Ali T, Ullah N, Kim MO., 2015. Caffeine prevents D-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain. Neurochem Int 90: 114-124.
257. Underwood E., 2015. The final countdown. Science 350: 1188-1190.
258. Vacca JP., 2012. Approaches toward new Alzheimer's treatments. ACS Med Chem Lett 3: 861.
259. Vahid F, Zanda H, Nosrat-Mirshekarlou E, Najafi R, Hekmatdoost A., 2015. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review. Gene 562: 8-15.
260. van de Mark K, Chen JS, Steliou K, Perrine SP, Faller DV., 2003. α- Lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J Cell Physiol 194: 325-340.
261. Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM., 2016. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. Curr Opin Neurobiol 36: 74-81.
262. Vinters HV., 2015. Emerging Concepts in Alzheimer's Disease. Annu Rev Pathol Mech Dis 10: 291-319.
263. Volmar C-H, Wahlestedt C., 2015. Histone deacetylases (HDACs) and brain function. Neuroepigenetics 1: 20-27.
264. Vos SJB, Fagan AM., 2016. Alzheimer's disease biomarker states. Lancet Neurol 15: 25-26.
265. Wagner FF, Weïwer M, Lewis MC, Holson EB., 2013. Small molecule inhibitors of zinc-dependent histone deacetylases. Neurotherapeutics 10: 589-604.
266. Wallace DC., 2013. A mitochondrial bioenergetic etiology of disease. J Clin Invest 123: 1405-1412.
267. Watts JC, Condello C, Stöhr J, Oehler A, Lee J, DeArmond SJ, Lannfelt L, Ingelsson M, Giles K, Prusiner SB., 2014. Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proc Natl Acad Sci USA 111: 10323-10328.
268. Wei H, Liu L, Chen Q., 2015. Selective removal of mitochondria via mitophagy: distinct pathways for different mitochondrial stresses. BBA-Mol Cell Res 1853: 2784-2790.
269. Weisfeld-Adams JD, Sand IBK, Honce JM, Lublin FD., 2015. Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain 138: 517-539.
270. Wiley JC, Pettan-Brewer C, Ladiges WC., 2011. Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. Aging Cell 10: 418-428.
271. Wimo A, Winblad B, Jönsson L., 2010. The worldwide societal costs of dementia: estimates for 2009. Alzheimer's Dement 6: 98-103.
272. Wisniewski T, Goñi F., 2015. Immunotherapeutic approaches for Alzheimer's disease. Neuron 85: 1162-1176.
273. Woo JA, Zhao X, Khan H, Penn C, Wang X, Joly-Amado A, Weeber E, Morgan D, Kang DE., 2015. Slingshot-Cofilin activation mediates mitochondrial and synaptic dysfunction via Aβ ligation to β1-integrin conformers. Nat Cell Differ 22: 921-934.
274. Wu Y-T, Fratiglioni L, Matthews FE, Lobo A, Breteler MMB, Skoog I, Brayne C., 2016. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neuro 15: 116-124.
275. Wurtman R., 2015. Biomarkers in the diagnosis and management of Alzheimer's disease. Metabolism 64: S47-S50.
276. Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, Bolshakov VY, Shen J, Kelleher RJ III., 2015. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease. Neuron 85: 967-981.
277. Xu J, Chatterjee M, Baguley TD, Brouillette J, Kurup P, Ghosh D, Kanyo J, Zhang Y, Seyb K, Ononenyi C, et al., 2014. Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease. PLoS Biol 12: e1001923.
278. Youle RJ, van der Bliek A., 2012. Mitochondrial fission, fusion and stress. Science 337: 1062-1065.
279. Yu S, Khor TO, Cheung K-L, Li W, Wu T-Y, Huang Y, Foster BA, Kan YW, Kong A-N., 2010. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One 5: e8579.
280. Zachar Z, Marecek J, Maturo C, Gupta S, Stuart SD, Howell K, Schauble A, Lem J, Piramzadian A, Karnik S, et al., 2011. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med 89: 1137-1148.
281. Zaitone SA, Abo-Elmatty DM, Shaalan AA., 2012. Acetyl-L-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy. Pharmacol Biochem Behav 100: 347-360.
282. Zhang H, Luo Q, Gao H, Feng Y., 2015. A new regulatory mechanism for bacterial lipoic acid synthesis. MicrobiologyOpen 4: 282-300.
283. Zheng X, Hunter T., 2014. Pink1, the first ubiquitin kinase. EMBO J. 33: 1621-1623.